Warfarin Management Suite

Clinical Guidance

TTR-Based Action Guide

Recommendations based on current TTR and selected indication. Always use clinical judgement.

Excellent TTR (>75%)

On Target

Continue current warfarin dose
Monitoring interval can be extended to 6-8 weeks
Patient is well anticoagulated, low thromboembolic and bleeding risk
Reinforce medication adherence and dietary consistency

Good TTR (65-75%)

Acceptable

Review for modifiable causes of variability
Check adherence, drug interactions, dietary changes
Consider more frequent monitoring (every 2-4 weeks)
May be acceptable for some indications

Suboptimal TTR (50-65%)

Action Needed

Systematic review of all contributing factors required
Medication reconciliation, alcohol, illness enquiry
Weekly INR monitoring for 4-6 weeks
Consider DOAC switch if AF (NICE CG196)

Poor TTR (<50%)

Urgent Review

Patient is NOT effectively anticoagulated
Urgent consultant review recommended
Strong case for DOAC switch if eligible (AF, VTE)
If warfarin mandatory (mechanical valve), refer to anticoagulation clinic

When to Consider Switching from Warfarin to a DOAC

NICE CG196 / NHS England guidance

DOAC Eligible

Atrial fibrillation (non-valvular)
VTE treatment and prevention
TTR consistently below 65%
Patient preference for no INR monitoring
Difficulty accessing anticoagulation clinics

Must Stay on Warfarin

Mechanical heart valves
Moderate-severe mitral stenosis
Antiphospholipid syndrome (triple positive)
Severe renal impairment (CrCl <15 mL/min)
Well-controlled on warfarin (TTR >75%)

Perioperative Warfarin Management

BSH Guideline 2016 — Keeling, Tait & Watson | BJH 2016;175:602–613

Elective Surgery — Stopping Warfarin

1C Stop warfarin 5 days before elective procedure if anticoagulation needs to be discontinued
Check INR the day before surgery. Give oral phytomenadione (vitamin K) if INR is ≥1.5 to reduce cancellation risk
INR should be checked on the day of surgery
Warfarin can be resumed at normal maintenance dose (or 2× maintenance) on the evening of surgery or next day if haemostasis is adequate

Bridging Therapy — When to Consider

Bridging = treatment dose LMWH or UFH while warfarin is temporarily stopped. Thromboprophylaxis dose LMWH is NOT bridging.

Indication	Consider Bridging When...
VTE	VTE within previous 3 months; very high risk patients (e.g. on therapeutic anticoagulation with target INR 3.5)
AF	Previous stroke/TIA in last 3 months; previous stroke/TIA plus ≥3 of: heart failure, hypertension (>140/90), age >75, diabetes mellitus
MHV	All MHV patients other than those with a bileaflet aortic valve and no other risk factors

Key Recommendations — Bridging Decisions

2C VTE >3 months ago: give post-op prophylactic dose LMWH (or suitable alternative) rather than bridging therapy
2D Very high risk VTE (e.g. VTE <3 months, on therapeutic anticoagulation with target INR 3.5): consider bridging
1A AF with CHA₂DS₂-VASc ≤4 and no stroke/TIA in last 3 months: do NOT bridge
2C Bileaflet aortic MHV with no other risk factors: no bridging required. Consider bridging in all other MHV patients
1C Post-operative bridging should not be started until at least 48 h after high bleeding risk surgery

Pre-operative Bridging Protocol (Timeline)

Day −5 before surgery

Stop warfarin. Start therapeutic LMWH when INR drops below therapeutic range (usually Day −3 or Day −2).

Day −1 (evening before surgery)

Give the last dose of LMWH at least 24 hours before the procedure. If on a once-daily regimen, consider giving half the usual dose for high bleeding risk surgery.

Day 0 (day of surgery)

Check INR on the morning of surgery. Proceed if INR ≤ 1.5. Restart warfarin on the evening of surgery (or next day) if haemostasis is secure.

Post-op Day 1–2+

Give prophylactic-dose LMWH if indicated. Do not restart full-dose (therapeutic) LMWH until at least 48 hours after high bleeding risk surgery. Continue bridging until INR is back in therapeutic range for 2 consecutive days.

Emergency Surgery on Warfarin

If surgery can wait 6–8 h: give IV phytomenadione (vitamin K) 5 mg to restore coagulation factors
If surgery cannot wait: reverse with 4-factor PCC 25–50 units/kg (give at the lower end and check INR)
Post-operative management follows the same strategy as for elective surgery

Procedures That May NOT Require Stopping Warfarin

For some procedures, the bleeding risk is low enough that anticoagulation may not need to be stopped. The operating surgeon, dentist, or interventional radiologist should assess the bleeding risk individually.

Dental procedures Joint injections Cataract surgery Pacemaker insertion Certain endoscopic procedures

Warfarin for Anticoagulation — Primary Care Prescriber Guidance

Information Sheet for Primary Care Prescribers — January 2025

Warfarin is an anticoagulant with a narrow therapeutic index. Regular titration of dose against the anticoagulant effect, as assessed by the INR, is essential. This guidance covers indications, initiation, maintenance, monitoring, drug interactions, and management of over-anticoagulation.

Indications — Target INR, Therapeutic Range & Duration

Indication	Target INR	Range	Duration
Pulmonary embolus	2.5	2.0–3.0	3 months to long term (if unprovoked)
Proximal DVT	2.5	2.0–3.0	3 months to long term (if unprovoked)
Distal DVT — isolated calf vein	2.5	2.0–3.0	6 weeks
Distal DVT — provoked by surgery/transient risk	2.5	2.0–3.0	3 months
Recurrent VTE — off warfarin or sub-therapeutic	2.5	2.0–3.0	6 months to long term
Recurrent VTE — on warfarin in therapeutic range	3.5	3.0–4.0	Long term
Non-valvular AF (CHA₂DS₂-VASc ≥2)	2.5	2.0–3.0	Long term
AF secondary to valvular (mitral stenosis) heart disease	2.5	2.0–3.0	Long term
Cardioversion for AF	2.5	2.0–3.0	Min 3 weeks before to 4 weeks after
Rheumatic mitral valve disease	2.5	2.0–3.0	Long term
Dilated cardiomyopathy	2.5	2.0–3.0	Long term
LV mural thrombus post MI ± LV aneurysm	2.5	2.0–3.0	3 months
Mechanical Prosthetic Heart Valves (MHV)
Low thrombogenicity — no patient risk factors	2.5	2.0–3.0	Long term
Low thrombogenicity — with patient risk factors	3.0	2.5–3.5
Medium thrombogenicity — no patient risk factors	3.0	2.5–3.5
Medium thrombogenicity — with patient risk factors	3.5	3.0–4.0
High thrombogenicity — no patient risk factors	3.5	3.0–4.0
High thrombogenicity — with patient risk factors	3.5	3.0–4.0
Inherited thrombophilia with DVT/PE	2.5	2.0–3.0	Variable
Antiphospholipid syndrome	2.5	2.0–3.0	Long term

Low thrombogenicity valves: Carbomedics (aortic), Medtronic Hall, St Jude Medical (without Silzone) | Medium: Bjork-Shiley, other bileaflet valves | High: Starr-Edwards, Omniscience, Lillehei-Kaster
Patient risk factors: mitral/tricuspid/pulmonary position; previous arterial TE; AF; left atrium >50 mm; mitral stenosis; LVEF <35%; left atrial dense spontaneous echo contrast.

Warfarin Initiation Schedule

Pre-initiation baseline bloods: FBC, coagulation screen, liver function tests (LFT), U&E (creatinine clearance).

When starting warfarin, stop antiplatelet therapy (aspirin, clopidogrel, dipyridamole, ticagrelor, prasugrel) once INR is within therapeutic range, unless continuation is explicitly advised by secondary care.

Day	INR (9–10 am)	Standard Dose (5–7 pm)	Reduced Dose*
1	—	9 mg	6 mg
2	—	9 mg	6 mg
3	<1.3	12 mg	9 mg
	1.3–1.6	9 mg	6 mg
	1.7–2.1	6 mg	4.5 mg
	2.2–2.5	4.5 mg	3 mg
	2.6–3.1	3 mg	1.5 mg
	3.2–3.5	1.5 mg	Nil
	>3.5	Nil	Nil
4	Guide to predicted daily maintenance dose
	<1.4	9 mg (or more)
	1.4–1.7	7.5 mg
	1.8–2.1	6 mg
	2.2–2.6	4.5 mg
	2.7–3.7	3 mg
	3.8–4.5	Nil × 1 day, then 1.5 mg
	>4.5	Nil × 2 days, then 1.5 mg or less per INR

*Reduced dose schedule: Use if age >70, weight <50 kg, heart failure, or liver disease.
Check INR on Day 6 (or earliest possible working day). Subsequent dose and re-test interval according to INR. Dosage decisions should be supported by approved clinical decision support software (CDSS), but clinical judgement must always be applied.

Maintenance Dosage

Maintenance dose is variable between patients but usually lies between 3 mg and 9 mg daily
Patients should take warfarin at a regular time each day, usually at 18:00
A late afternoon or evening dose allows same-day INR results to inform dose adjustment before the patient takes their next dose
Fine tuning may require alternate-day regimens (e.g. 4.5 mg / 3 mg on alternate days) if INR fluctuates
All dosing instructions must be written in the patient's Anticoagulation Therapy Booklet or single sheet therapy record (SSTR)
As a guide: a 15% change in weekly dose is expected to shift the INR by approximately 1 unit; a 10% change shifts INR by about 0.7–0.8

Missed Dose

If a patient misses a dose, they should NOT take a double dose the next day. Continue with their normal dose. Patients who are very sensitive to changes, or at high risk if under-dosed, should contact the anticoagulation service as soon as possible.

Contraindications

Recent haemorrhagic stroke or other intracerebral bleeding
Significant active bleeding
Uncontrolled severe hypertension (systolic ≥200 mmHg; diastolic >110 mmHg)
Bleeding peptic ulcer disease
Excessive alcohol intake with binge drinking
Pregnancy — warfarin exposure at 6–12 weeks gestation can cause embryopathy; ongoing risk of foetal haemorrhage throughout. Women of childbearing age must be counselled on effective contraception

Relative Contraindications — Discuss Before Prescribing

History of GI bleeding Uncontrolled hypertension Liver disease (abnormal coag screen) Oesophageal varices ESRF (GFR <15) — discuss with renal team Cancer — discuss with oncology Infective endocarditis HHT — discuss with haematology Bleeding disorders — discuss with haemophilia team Platelets <100 — discuss with haematology Inability to monitor INR Concomitant drugs increasing bleed risk

Precautions & High Bleeding Risk Factors

Caution is needed in patients with severe heart failure, liver failure, DVT/PE in the previous month, thyroid disorders, and chronic alcohol intake. Seek advice from the Anticoagulation Clinic where needed.

Age >65 Uncontrolled hypertension Diabetes Renal failure Previous MI/CVA Previous GI/cerebral bleed Liver disease

MHRA Safety Alert: Calciphylaxis — a rare but serious condition causing vascular calcification and skin necrosis — has been reported with warfarin. The mortality rate is high. Advise patients to seek urgent medical advice if they develop a painful skin rash.

Monitoring Requirements

Baseline Blood Tests (all patients before starting)

U&E (creatinine clearance) FBC Coagulation screen LFTs

Follow-up INR Monitoring

Maximum interval between tests: 12 weeks for stable patients
Test more frequently if clinical condition is changing, new medications started, or dosage altered
Consider annual FBC, U&E, and LFTs for long-term patients — detects anaemia (occult bleeding) and thrombocytopenia

At Each INR Visit — Ask the Patient:

☑ Any signs of bleeding or bruising?
☑ Planning any dental or surgical procedures?
☑ Have they followed their advised dosage instructions?
☑ Any change in medications or dietary habits since last test?

TTR Review Pathway

Use a validated method (Rosendaal or proportion-in-range). Exclude the first 6 weeks of treatment. Calculate TTR over a maintenance period of at least 6 months.

TTR ≥ 65% — Consider flags

☐ Intolerance or allergy to VKA?
☐ History of significant bleed with poor warfarin control?
☐ 1 × INR >8 in last 6 months?
☐ 2 × INR >5 in last 6 months?
☐ 2 × INR <1.5 in last 6 months?

If NO flags → Continue dose-adjusted warfarin. Review stroke/bleed risk at annual review.

TTR < 65% — Address causes

☐ Cognitive function
☐ Adherence to prescribed therapy
☐ Intercurrent illness
☐ Interacting drug therapy
☐ Diet and alcohol lifestyle factors
☐ Consider self-monitoring (NICE)

Reassess after appropriate interval. If still <65% → consider DOAC switch or refer to anticoagulation clinic/haematology.

Drug Interactions with Warfarin

This list is not exhaustive — refer to BNF for full details. If any of these drugs are started in a patient on warfarin, consider alternatives in the same class. If not possible, monitor INR within 72 hours of starting and on withdrawal.

▲ Drugs that INCREASE the INR and Risk of Bleeding

Gastrointestinal	Cimetidine INH, omeprazole INH, esomeprazole
Cardiovascular	Amiodarone INH (slow inhibition — may persist weeks after withdrawal; monitor weekly for ≥4 weeks), fibrates, ezetimibe, propafenone INH, propranolol, statins (prudent to check INR after initiation/dose change)
CNS	Entacapone, fluvoxamine INH, SNRIs, SSRIs INH, tramadol
Anti-infectives	Azole antifungals INH (esp. miconazole incl. oral/vaginal), co-trimoxazole INH, macrolides INH, metronidazole INH, quinolones INH, tetracyclines, influenza vaccine
Endocrine	Anabolic steroids (and danazol), high-dose corticosteroids, glucagon (high dose ≥50 mg over 2 days), flutamide, levothyroxine
NSAIDs	Ibuprofen at lowest effective dose (±PPI) if NSAID required. All NSAIDs can increase bleeding risk and should be avoided if possible
Antiplatelets	Aspirin, clopidogrel, dipyridamole, ticagrelor, prasugrel
Anticoagulants	Fondaparinux, heparin, LMWH (e.g. enoxaparin, tinzaparin); DOACs (apixaban, dabigatran, rivaroxaban)
Cytotoxics	Erlotinib, etoposide, fluorouracil, gefitinib, gemcitabine, imetinib, sorafenib, vemurafenib
Miscellaneous	Alcohol (acute), actiretin, allopurinol INH, benzbromarone INH, colchicine, disulfiram, interferon, paracetamol (high dose prolonged use), sulfinpyrazone, tamoxifen, topical salicylates, zafirlukast INH
Herbal / Food	Carnitine, chamomile, cranberry juice INH, curbicin, dong quai, fenugreek, fish oils, garlic, ginkgo biloba, glucosamine, grapefruit juice INH, lycium INH, mango, quilinggao

▼ Drugs that DECREASE the INR

Miscellaneous	Alcohol (chronic) IND, azathioprine, barbiturates IND, bosentan IND, carbamazepine IND, carbimazole, griseofulvin IND, mercaptopurine, nevirapine IND, OCP/HRT, phenobarbital, phenytoin, propylthiouracil, raloxifene, rifampicin IND (most potent inducer), trazodone
Herbal	Avocado, co-enzyme Q10, green tea, natto, soya beans, St John's Wort IND (avoid)
Binding agents	Colestyramine, sucralfate
Warfarin antagonist	Vitamin K

▲▼ Drugs that may INCREASE or DECREASE the INR

Anti-virals	Atazanavir, efavirenz, ritonavir, telapravir
Miscellaneous	Ginseng, phenytoin, quinidine, tricyclic antidepressants

If a patient on warfarin is started on ANY new medication, a repeat INR after 1 week is sensible.

Abbreviations: INH Liver enzyme inhibitor (fast onset — check INR within 72 h) IND Liver enzyme inducer (slower onset 2–3 weeks — check INR after 1 week; effect persists up to 4 weeks after stopping)

Over-anticoagulation & Bleeding Management

ANY SIGNS OF BLEEDING REQUIRE MEDICAL ADVICE AND/OR DIRECT REFERRAL TO SECONDARY CARE.

Investigate for cause of high INR: drug interaction, alcohol, altered diet, cardiac failure, intercurrent illness, renal failure, liver disease. Exclude intracranial bleeding by asking about headache, nausea/vomiting, blurred vision, memory loss, personality change — if concern, arrange urgent admission.

INR / Scenario	Recommended Action
Major bleeding irrespective of INR	Urgent referral to secondary care
Minor bleeding (minor trauma, nose bleeds), INR <5.0	Seek advice from GP or specialist. Reduce warfarin dose appropriately. If minor bleeding persists despite INR in range, review the plan for anticoagulation (e.g. brief warfarin interruption)
Minor bleeding, INR >5	Stop warfarin, refer to secondary care
INR 3.0–6.0 (target 2.5), no bleeding	Reduce weekly warfarin dose by 10–20%. Repeat INR in 1–2 weeks
INR 4.0–6.0 (target 3.5), no bleeding	Reduce weekly warfarin dose by 10–20%. Repeat INR in 1–2 weeks
INR 6.0–8.0, no bleeding	Stop warfarin for 1–2 days, reduce weekly dose by 50%. Consider oral phytomenadione (vitamin K) 2 mg if bleeding risk factors*. Check INR within 7 days (or next day after vitamin K)
INR >8.0, no bleeding	Stop warfarin. Give oral phytomenadione (vitamin K) 2 mg. Check INR the following day — repeat vitamin K if still high. Restart warfarin at appropriate dose when INR is back in range. Check INR within 7 days

*Bleeding risk factors: age >70, previous history of bleeding, abnormal LFTs, malignancy, tendency to falls.
For CoaguChek XS Plus: when INR >8.0, confirm with a second capillary test AND a venepuncture sample sent to lab. Do not delay clinical decisions while awaiting lab confirmation.

INR Below Target Value

Check compliance, investigate interacting medication (prescribed, OTC, herbal) and dietary/lifestyle changes
Decide on individual case basis whether to increase dose or address the cause. Retest INR in 7–14 days
If INR falls outside therapeutic range within the first 4 weeks of acute VTE, seek advice from haematology regarding LMWH cover
If >2 INRs remain below range despite intervention, seek specialist advice (e.g. cardiologist for artificial valve patients)

Patient Counselling Checklist

At the first appointment (transfer from secondary care or primary care initiation), ensure the patient and/or carer is fully informed. Issue a hand-held Anticoagulation Therapy book and alert card.

☑ Drug name and current dose

☑ Reason for anticoagulation

☑ Target INR and therapeutic goal

☑ Anticipated duration of treatment

☑ What to do if a dose is missed

☑ Signs of under/over-anticoagulation

☑ Drug/drug and drug/food interactions

☑ Monitoring arrangements

☑ Dental/surgical procedure advice

☑ Women: contraception counselling

Warfarin Tablet Strengths & Colour Coding

0.5 mg — White 1 mg — Brown 3 mg — Blue 5 mg — Pink

To minimise risk, many organisations use only warfarin 3 mg (blue) tablets as a standardised approach. In exceptional circumstances (high sensitivity), the 1 mg (brown) tablet may be used. Multiple strengths should not be used concurrently.

Did Not Attends (DNAs) & Discontinuation

A robust system must be in place to follow up all DNAs. Stress to the patient that careful monitoring is essential to avoid complications
Where patients repeatedly fail to attend, the risks of continuing therapy should be weighed against the benefits
Consider early discontinuation if the risks outweigh benefits — e.g. patients not attending regular monitoring or unable to follow dosing regimen

Patient Self-Testing & Self-Management (PST/PSM)

BSH Guideline 2014 — Jennings et al. | BJH 2014;167:600–607

What Are PST and PSM?

Patient Self-Testing (PST)

The patient uses a point-of-care testing (POCT) device to measure their own INR at home, then communicates the result to a healthcare professional who interprets it and decides the dose.

Patient Self-Management (PSM)

The patient measures their own INR and interprets the result and adjusts their own warfarin dose using a simple dosing algorithm. This requires additional training and demonstrated competency.

Clinical Evidence — Why Consider PST/PSM?

Meta-analysis of 22 trials (8,413 patients): PST/PSM associated with lower total mortality (OR 0.74), lower risk of major thromboembolism (OR 0.58), and no increased risk of major bleeding (OR 0.89)
Cochrane review (18 RCTs, 4,723 participants): significant reductions in thromboembolic events (RR 0.50) and all-cause mortality (RR 0.64)
PSM patients showed significant reductions in thromboembolic events (RR 0.47) and all-cause mortality (RR 0.55); PST reduced thromboembolic events (RR 0.57) and major haemorrhage (RR 0.56)
TTR improvement at 1 year: 2.7% for heart valve patients, 5.1% for AF patients compared to standard care
In 8 of 11 trials, patient satisfaction and/or quality of life were reported as better with PST/PSM

Patient Selection & Training

Patient selection should be based on: anticoagulation for >12 months, willingness to participate in training (patient or carer), and ability to demonstrate competence. Failure to complete training has been linked to CVA history, poor cognition, low literacy, and poor manual dexterity. UK studies show 75% of patients can successfully complete training programmes.

Training Programme Should Cover:

☑ Anticoagulation management theory

☑ How and when to monitor INR

☑ Problems with monitoring

☑ Drug and food interactions

☑ Diet, alcohol, illness and travel

☑ Recognising & treating complications

☑ Target INR and keeping within 0.5 of target

Practical Training Must Include:

☑ Operating the coagulation monitor

☑ Practising a coagulation test

☑ Performing IQC test

☑ Fingerstick technique

☑ Identifying sources of error

☑ Recording test results

Quality Assurance for PST/PSM

Internal Quality Control (IQC)

Three types: electronic QC, on-board QC, and liquid QC — perform all that are available
Liquid IQC target INR should be 2.0–4.0; repeat measurements should be within 0.5 INR of each other and within manufacturer's target range
Run IQC when: new batch of test strips, unexpectedly high or low result with no clinical explanation, and at least every 6 months
If IQC fails twice, suspend PST and contact the healthcare provider responsible for anticoagulant care

External Quality Assessment (EQA) — at least every 6 months (2C)

Option 1: Test fingerstick on patient's device AND a clinic device (same type) — results within 0.5 INR of each other
Option 2: Test fingerstick AND venous sample sent to lab simultaneously — results within 0.5 INR (stable patients in range only)
If INR between 4.5–8.0 on POCT, repeat test. If >8 confirmed on repeat, seek medical advice promptly and send venous sample to lab

Follow-up & Review

Follow-up review is agreed on an individual basis by the responsible clinician
Patient should be seen at least every 6 months — review INR results, dates, QC results, and any problems
The yellow record book used widely by anticoagulant clinics can be used by the patient to record INR results and next test date
ISTH recommends PST/PSM should be considered for children receiving long-term VKA therapy (>3 months), especially those transitioning to adult services

BSH Key Recommendations

1C Motivated patients on long-term warfarin can be considered for PST/PSM. They need to demonstrate competency and be trained to a standard acceptable to both patient and clinician
1C The POCT device selected should have had an acceptable evaluation by an expert body (e.g. NHS Supply Chain) and be acceptable to the responsible healthcare professional
2C An agreement should be signed by the patient and healthcare professional; review at least every 6 months with documentation of results and dosing
1C Patients self-managing should have demonstrated competence in dose adjustment using a simple warfarin dosing algorithm
2C If liquid IQC samples are available, they should be run at least when testing a new batch of strips, when an unexpectedly high/low result occurs, and at least every 6 months
2C EQA should take place at least every 6 months. An INR >8.0 (confirmed on repeat) requires a venous sample sent to lab and prompt medical advice

Mechanical Heart Valves (MHV) in Pregnancy

BSH Guideline 2023 — Lester, Walker et al. | BJH 2023;202:465–478

Very High-Risk Pregnancy

UKOSS data: maternal mortality 9%, severe morbidity 41%, valve thrombosis 16%, cerebrovascular accident 9%. Only 28% had a good maternal and foetal outcome. The ROPAC registry showed 58% chance of live birth. Pregnancy in individuals with MHV requires management in a specialist tertiary centre with an experienced MDT including obstetrics, cardiology, cardiac surgery, anaesthetics, neonatology, and haematology.

All BSH Recommendations with GRADE Evidence

'Should' = strong recommendation | 'Recommends' = conditional recommendation

Pre-Pregnancy Counselling

1D Individuals with a MHV of childbearing age should be offered pre-pregnancy counselling as soon as appropriate
1D Prior to cardiac surgery, all individuals of childbearing age should be counselled about the impact of valve replacement choice on future pregnancy risk
1D Anticoagulation options, including risks and benefits to the mother and the foetus, should be discussed, and a written management plan incorporating patient preference should be agreed
1D Low adherence with chosen anticoagulant strategy is a common cause of morbidity and mortality; this should be a key component of pre-pregnancy counselling with measures to support adherence during pregnancy and postpartum

MDT Management

2C Individuals with MHV who are pregnant should be managed in a designated specialist centre with an experienced MDT including obstetrics, cardiology, cardiac surgery, anaesthetics, neonatology, and haematology

Choice of Anticoagulant Regimen

1C Vitamin K antagonists (VKAs) are superior to LMWH for preventing MVT in pregnancy and are recommended as optimal therapy for improving maternal outcomes
2C There is insufficient evidence to recommend that lower doses of warfarin (e.g. less than 5 mg) are safe in terms of adverse foetal outcome
2C When using VKAs in pregnancy, non-pregnancy INR targets can be used. INR should be checked at least weekly if unstable and at least fortnightly with the option of self-testing when appropriate
2C When switching from VKA to LMWH in pregnancy, the starting dose of LMWH should be higher than standard (e.g. enoxaparin 2.5 mg/kg/day, dalteparin 250 IU/kg/day, tinzaparin 250 IU/kg/day in divided doses) due to high rate of MVT during transition in the first trimester
2C Regular monitoring using an anti-Xa assay is recommended. A peak anti-Xa target of 1.0-1.4 IU/mL taken 3-4 h following a BD (twice daily) dose is a reasonable compromise. Routine use of specific trough levels or more than twice daily dosing is not currently recommended
2C We recommend the addition of low-dose aspirin (LDA) 75 mg to anticoagulation with LMWH in individuals with MHV during pregnancy in the absence of a contraindication
2D An increase in the dose of aspirin to 150 mg at 12-week gestation can be considered if indicated for prevention of pre-eclampsia

Miscarriage & Termination of Pregnancy

2C Surgical management is recommended for miscarriage and termination of pregnancy in the first trimester (non-surgical options have reduced success rates, higher need for unplanned surgical evacuation, and increased bleeding in anticoagulated patients)

Mechanical Valve Thrombosis (MVT)

2C MVT requires MDT management in a specialist centre with the use of thrombolysis where appropriate

Delivery & Peripartum Management

2C There is insufficient evidence to recommend a specific mode of delivery. An individualised plan for timing and mode of delivery should be agreed in advance with input from the MDT and the pregnant individual
2C Documented delivery and emergency plans should be easily available, and a copy carried by the pregnant individual, for unplanned attendances at any maternity unit
1C VKAs should be switched to heparin at least 2 weeks prior to anticipated delivery and by 36 weeks at the latest
2C If presenting in labour and on VKA within 2 weeks of scheduled delivery, a caesarean birth should be considered to decrease foetal bleeding complications from labour
1B Therapeutic LMWH should be paused for at least 24 h prior to surgical delivery to facilitate neuraxial analgesia/anaesthesia
2C Prolonged pre-delivery interruption of anticoagulation should be avoided. Consider a prophylactic or intermediate dose LMWH or IV UFH during induction of labour after MDT discussion with haematology and anaesthetic teams
2C In view of the high risk of PPH, consider stopping aspirin at least 3 days prior to scheduled delivery

Postpartum Anticoagulation

2C Prophylactic or intermediate doses of LMWH for the first 24-48 h postpartum are recommended. Restarting a VKA around days 5-7 should be considered to balance the risk of thrombosis against major bleeding
2C If using UFH postpartum, a gradual increase in anticoagulant intensity is recommended for the first few days
2C Postpartum, individuals should not leave hospital without a plan for contraception. Insertion of an IUD or implant may be suitable for some individuals at the time of delivery or on the postnatal ward
2C Postnatal follow-up is recommended where the pregnancy can be reviewed and plans made for any future pregnancies

Risk Factors for Thrombosis with MHV

Prosthesis Thrombogenicity	Other Factors Increasing Thrombosis Risk
Lower Risk	Mitral, tricuspid or pulmonary replacement Previous thromboembolism Valve dysfunction/mismatch Left ventricular dysfunction Atrial fibrillation Poor adherence with medication
Carbomedics, Medtronic Hall, St Jude Medical, On-X
Medium Risk
Other bi-leaflet valves
Higher Risk
Lillehei-Kaster, Omniscience, Starr-Edwards, Bjork-Shiley, other tilting-disc valves

Adapted from Vahanian et al. (ESC/EACTS 2021 Guidelines)

Anticoagulation Regimens: Maternal vs Foetal Risks

Regimen	Maternal Benefits/Risks	Foetal Benefits/Risks
Warfarin throughout (switch to LMWH from 36 wk)	Lowest composite maternal risk (5%) Lowest mortality rate 0.9% Lowest thromboembolic complications 2.7% (1.4-4%) Increased risk of bleeding in some studies (antepartum and postpartum)	Highest overall foetal loss (32.54%) Highest composite foetal risk (miscarriage, termination, foetal abnormality) 39% Live births 83.6% with warfarin <5 mg/day, 43.9% with >5 mg/day Embryopathy/fetopathy 2.3% (<5 mg) to 12.4% (>5 mg) Risk of foetal intracranial haemorrhage with vaginal delivery if recent (<1 week) warfarin dosing
LMWH throughout	Higher composite maternal risk (15.5%) Higher mortality rate 2.9% (0.2-5.7%) Higher thromboembolic complications 8.7% (3.9-13.4%), reported up to 53% Optimal dosing with anti-Xa levels not fully established; close monitoring required	Lowest composite foetal risk (13%) Overall foetal loss rate 12.2% to 13.9% Highest livebirth rate 92% (86.1-98%) No placental transfer to foetus during pregnancy
Combination LMWH from +ve test to wk 13, warfarin wk 13-36, LMWH to delivery	Similar composite maternal risk to LMWH alone (15.9%) Mortality rate 2% (0.8-3.1%), lower than LMWH throughout MVT risk higher than warfarin 50% of MVT occur during first trimester LMWH transition Thromboembolic complications 5.8% (3.8-7.7%) Requires very close monitoring during transitions	Composite foetal risk 23% Overall foetal loss rate 22.65% Fetopathy (foetal haemorrhage) 1.4% (0.3-2.5%) Live birth 79.9% (74.3-85.6%) Better livebirth rate than warfarin >5 mg/day No placental transfer during first trimester
UFH only	Very rarely recommended due to MVT >10% (11.2%) Risk of maternal osteoporosis and thrombocytopenia	Low rate of live births Small number of pregnancies analysed
DOACs (dabigatran, rivaroxaban, apixaban, etc.)	Not effective as warfarin in MHV patients Cross the placenta Not recommended	Limited evidence, currently contraindicated Not recommended in breast feeding

Pre-Pregnancy Counselling Checklist

☑ Valve type, number of MHVs, indication and age of valve
☑ Adherence with prior anticoagulant therapy
☑ Risk stratification for thrombotic events (MVT) based on prosthesis and patient factors
☑ Detailed discussion of risks associated with pregnancy and anticoagulation options
☑ Early effects of VKAs/warfarin on foetal development (from 6 weeks gestation)

☑ Importance of early pregnancy testing and early contact with specialist team
☑ The chosen anticoagulation regimen planned in detail with awareness of adherence needs
☑ Risks of unplanned pregnancy; signpost to family planning/GP for effective contraception
☑ Preconception: folic acid, vitamin D, healthy lifestyle, medication review
☑ Patients with congenital heart disease: increased risk of CHD in newborn
☑ Written summary for patient and GP including how to contact the specialist team

Pregnancy Management Timeline

Positive Pregnancy Test (Urgent Referral)

Refer to specialist MDT as a matter of urgency. Ideally reviewed by MDT before 6 weeks gestation. If on VKA and plan includes first trimester LMWH: stop VKA, start twice-daily LMWH at higher-than-standard doses. The INR need not be in normal range when commencing LMWH. If pre-pregnancy written care plan exists, follow it. If not, create one now.

First Trimester (Weeks 1-13) — Highest MVT Risk

If on LMWH: Monitor anti-Xa levels at least weekly until target achieved, then every 2-4 weeks when stable. Peak anti-Xa target: 1.0-1.4 IU/mL at 3-4 h post BD dose. Add aspirin 75 mg daily (increase to 150 mg at 12 weeks if indicated for pre-eclampsia prevention).
If on VKA throughout: Check INR at least weekly if unstable, fortnightly when stable. Use non-pregnancy INR targets. Consider self-testing.

Second & Third Trimester (Weeks 13-36)

If combination regimen: Switch back from LMWH to warfarin at week 13. Continue VKA with regular INR monitoring until 36 weeks.
If LMWH throughout: Continue BD dosing with regular anti-Xa monitoring (every 2-4 weeks when stable). Dose escalation may be required (mean increase ~54% in one study).
By 36 weeks at the latest: Switch VKA to LMWH (or at least 2 weeks before planned delivery). This is the mandatory transition point.

Pre-Delivery (36 Weeks to Delivery)

Switch to therapeutic LMWH (or UFH). Last dose of therapeutic LMWH at least 24 h before planned induction/caesarean. Stop aspirin at least 3 days before scheduled delivery. During induction, consider prophylactic/intermediate dose LMWH or IV UFH to avoid prolonged interruption. For neuraxial anaesthesia: VKA requires INR ≤1.4; therapeutic LMWH requires 24 h interval; prophylactic LMWH requires 12 h interval; UFH requires minimum 4 h with normal APTTR and platelets.

Postpartum — Cautious Reintroduction

First 24-48 h: Prophylactic or intermediate doses of LMWH only (not full therapeutic).
Days 5-7: Restart VKA, overlapping with LMWH until therapeutic INR achieved. Timely recognition and MDT management of wound and intra-abdominal haematoma is important.
Breast feeding: Safe with UFH, LMWH, or VKAs.
Before discharge: Plan for contraception, postnatal cardiac review, postnatal follow-up, and discussion about future pregnancies.

LMWH Dosing & Monitoring in MHV Pregnancy

Parameter	Recommendation
Starting dose (higher than standard)	Enoxaparin 2.5 mg/kg/day BD \| Dalteparin 250 IU/kg/day BD \| Tinzaparin 250 IU/kg/day BD
Peak anti-Xa target	1.0-1.4 IU/mL taken 3-4 h after BD dose
Trough level (if monitored)	Target >0.6 IU/mL (considered arbitrary; more data needed). Those with levels >0.6 IU/mL and more than twice-daily dosing need evaluation
Monitoring frequency	At least weekly during initial transition until target level achieved or when below target. Then every 2-4 weeks when stable
Peak vs trough monitoring	Peak testing preferred by majority of haematology/thrombosis specialists (ISTH SSC survey). Routine trough levels not currently recommended to replace peak monitoring
Aspirin	LDA 75 mg daily added to anticoagulation (unless contraindicated). Consider increasing to 150 mg at 12 weeks for pre-eclampsia prevention if indicated

Foetal Complications of VKAs (Warfarin)

Warfarin Embryopathy (Foetal Warfarin Syndrome)

Nasal bone hypoplasia and skeletal abnormalities. Occurs with exposure between 6 and 12 weeks of gestation. Affects between 6% and 12% of foetuses exposed. Some studies suggest a dose-response relationship with lower rates at warfarin doses <5 mg/day, though data are not conclusive. Running the INR below target to keep warfarin dose <5 mg is not recommended due to increased MVT risk.

Other Foetal Risks Beyond First Trimester

Beyond the first trimester, VKA use is associated with foetal, placental, and neonatal haemorrhage. Warfarin crosses the placenta and the foetus is more anticoagulated than the mother due to immature vitamin K-dependent clotting factors. Neurodevelopmental effects are considered secondary to bleeding complications (e.g. intracerebral haemorrhage) rather than a direct teratogenic effect.

Diagnosis & Management of Mechanical Valve Thrombosis (MVT)

Clinical Features — Maintain Low Index of Suspicion

No longer hearing clicks from the valve closure, obstructive symptoms (breathlessness, heart failure, syncope, pre-syncope), cardiogenic shock, non-obstructive symptoms (embolic events: stroke, renal or splenic infarct, new onset abdominal pain). Right-sided valves may present with loss of appetite, lower limb oedema, ascites, and pulmonary emboli. Examination may reveal increased heart rate, low BP, quiet or absent mechanical valve sounds, a new murmur, and inspiratory crepitations. Urgent echo and cardiology review required.

Thrombolysis Criteria

Successful thrombolysis = at least 2 out of 3:
1. Resolution of elevated Doppler gradient
2. Reduction in thrombus size (>50%)
3. Improvement in symptoms

Alteplase (highest molecular weight >1000 Da, does not easily cross the placenta) is preferred. If unsuccessful, consider repeating if haemodynamically stable.

MVT with Stroke or Obstruction

With stroke: Emergency stroke team review. Senior MDT including obstetrics, cardiology, anaesthetics, cardiac surgery, neurology/stroke. Individualised care plan considering MVT, stroke, and pregnancy management needs.

With obstruction: If haemodynamically unstable, this is a clinical emergency. Consider cardiac surgical bypass (maternal mortality rate ~11.2%, foetal loss ~33.1%). Measures to reduce foetal risks: minimise hypothermia, maintain mean arterial pressure >70 mmHg, avoid maternal hypoglycaemia, left lateral tilt.

Anaesthetic Considerations

Anticoagulant	Neuraxial Blockade Interval	Notes
VKA (Warfarin)	INR must be ≤1.4	If presenting in labour on VKA, GA is usually administered when intervals not met
Therapeutic LMWH	≥24 h since last dose	If prophylactic dose given after therapeutic LMWH interruption, 12 h interval from prophylactic dose
Prophylactic LMWH	12 h since last dose	Epidural catheter removal: 12 h after last prophylactic dose
IV UFH	Minimum 4 h, with normal APTTR and platelet count	UFH monitoring in pregnancy is problematic (APTTR targets may differ from non-pregnant); anti-Xa calibrated assay recommended where available

Labour Analgesia Options

Non-neuraxial (no anticoagulation interruption needed): Paracetamol, dihydrocodeine, 50:50 nitrous oxide and oxygen, diamorphine, IV PCA with fentanyl or remifentanil. These are commonly used when a patient with MHV on therapeutic LMWH presents in spontaneous labour.
Neuraxial (requires anticoagulation interruption): Epidural, spinal, combined spinal-epidural, or dural puncture epidural. Superior analgesia and the advantage of extending to anaesthesia for emergency caesarean, but requires cessation of anticoagulation at specific intervals.

Neonatal Considerations

If presenting in labour and on VKA within previous 2 weeks, a caesarean birth should be considered to decrease foetal bleeding complications. Instrumentation and invasive foetal monitoring should be avoided. In very advanced labour, outlet forceps delivery may be less traumatic than a second-stage CS. Ventouse should not be used. Close liaison with the neonatology team is required, and a coagulation screen should be performed on the newborn. An INR above the age-appropriate reference range should be managed with IV vitamin K (30 mcg/kg by slow IV infusion) rather than the standard neonatal prophylactic dose, and FFP or 20-30 IU/kg PCC should be considered.

Postpartum Cardiology Care

Cardiac output peaks 24-48 h after birth, making heart failure symptoms more likely if there is left ventricular systolic dysfunction. Women with MHV need a tailored postnatal care and monitoring plan, including postnatal echocardiography as required. Pre-discharge INR testing arrangements and a plan for postnatal follow-up, pregnancy review, and future pregnancy planning should be in place.

Contraception

All postpartum individuals must leave hospital with a contraception plan agreed with the individual and MDT. Consider: risks of future pregnancy, reversibility, drug interactions, compliance, and cardiovascular risk. UK Medical Eligibility Criteria for Contraceptive Use applies. The guidance recommends against oestrogen-containing contraception in individuals with complex valvular and congenital heart disease. MHV increases thrombus formation risk, so long-acting reversible contraceptives are preferable in the postpartum period.

Assisted Conception (ART)

Assisted conception should not proceed without prior involvement of the specialist team who can recommend on the suitability, preparatory investigations, and management. ART involving ovarian stimulation is an additional risk factor for thrombosis. For invasive procedures associated with bleeding (e.g. egg collection), individuals on a VKA should be bridged with twice-daily therapeutic LMWH for the minimum period of time before restarting the VKA. There is insufficient evidence to support admission for UFH. The last dose of therapeutic LMWH should be ≥24 h before the scheduled procedure, and immediate post-procedure therapeutic anticoagulation should be avoided.

Postpartum Haemorrhage (PPH) — High Risk in MHV

PPH risk is high in this population. The UKOSS study reported: primary PPH 2%, secondary PPH 10%, wound haematoma 10%, intra-abdominal bleed 7%. Postpartum bleeding complications can lead to a paradoxical increase in thrombosis risk as anticoagulants have to be reversed or paused. The guideline recommends:

• In individuals at least partially anticoagulated (<24 h): low threshold for tranexamic acid 1 g IV post-delivery
• Otherwise, use as per normal PPH criteria. Avoid repeated doses of TXA beyond the two doses used in the WOMAN trial
• If using aspirin, stop at least 3 days prior to scheduled delivery (not mandated to stop, but consider the high PPH risk)
• Protamine is a reversal agent for UFH but has limited role for LMWH; risks include anaphylaxis, pulmonary oedema, bronchoconstriction, and paradoxically increased bleeding
• If presenting on VKA, correct INR with four-factor PCC (25-50 u/kg) in addition to vitamin K 10 mg IV. This is preferable to FFP which is only partially effective and requires higher fluid volume
• Uterotonic agents: Oxytocin is commonly used. Alternatives include sublingual/rectal misoprostol, prostaglandin F2-alpha (not with asthma, right heart dysfunction, pulmonary hypertension), and ergotamine (not with vasculitis, hypertensive disorders, coronary disease, or ventricular dysfunction)
• MDT approach with low threshold for imaging (CT scan) and intervention (re-exploration) to rule out surgical bleeding. Any unexpected fall in haemoglobin should be investigated quickly

Breast feeding can be safely undertaken on UFH, LMWH, or VKAs (warfarin).

Reference: Lester W, Walker N, Bhatia K, Ciantar E, Banerjee A, Trinder J, et al. British Society for Haematology guideline for anticoagulant management of pregnant individuals with mechanical heart valves. Br J Haematol. 2023;202(3):465-478. doi: 10.1111/bjh.18781

Reference

BNF Warfarin Monograph

Complete British National Formulary drug monograph for warfarin sodium. Click any section to expand.

BNF Drug Monograph

Warfarin Sodium

British National Formulary (BNF) — Complete Drug Monograph. Indications, dosing, safety alerts, contraindications, interactions, pregnancy, monitoring, and medicinal forms.

Source: NICE BNF

Indications and Dose

Indications

Prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation
Prophylaxis after insertion of prosthetic heart valve
Prophylaxis and treatment of venous thrombosis and pulmonary embolism
Transient ischaemic attacks

Dose — Adults (By mouth)

Induction

Initially 5–10 mg, to be taken on day 1; subsequent doses dependent on the prothrombin time, reported as INR (international normalised ratio).

Alternative Induction

A lower induction dose can be given over 3–4 weeks in patients who do not require rapid anticoagulation. Elderly patients should be given a lower induction dose.

Maintenance

3–9 mg daily, to be taken at the same time each day.

Important Safety Information

For all vitamin K antagonists

MHRA/CHM advice: Direct-acting antivirals to treat chronic hepatitis C — risk of interaction with vitamin K antagonists and changes in INR (January 2017)
An EU-wide review has identified that changes in liver function, secondary to hepatitis C treatment with direct-acting antivirals, may affect the efficacy of vitamin K antagonists. The MHRA has advised that INR should be monitored closely in patients receiving concomitant treatment.

MHRA/CHM advice: Warfarin and other anticoagulants — monitoring of patients during the COVID-19 pandemic (October 2020)
Healthcare professionals are reminded that:

Acute illness (including COVID-19 infection) may exaggerate the effect of warfarin and necessitate a dose reduction
Continued INR monitoring is important in patients taking warfarin or other vitamin K antagonists if they have suspected or confirmed COVID-19 infection
Vitamin K antagonists may interact with other medicines (including antibacterials and antivirals) — advice in product literature should be followed to minimise the risk of potential interactions
If patients are switched from warfarin to a DOAC, warfarin treatment should be stopped before DOAC treatment is started to reduce the risk of over-anticoagulation and bleeding

Patients on vitamin K antagonists should be reminded to carefully follow instructions for use and advised to notify their GP or healthcare team if they:

Have symptoms of, or confirmed, COVID-19 infection
Are otherwise unwell with sickness or diarrhoea, or have lost their appetite
Have changed their diet, smoking habits, or alcohol consumption
Are taking any new medicines or supplements
Are unable to attend their next scheduled blood test for any reason

For warfarin sodium specifically

MHRA/CHM advice: Warfarin — reports of calciphylaxis (July 2016)
An EU-wide review has concluded that on rare occasions, warfarin use may lead to calciphylaxis. Patients should be advised to consult their doctor if they develop a painful skin rash. If calciphylaxis is diagnosed, appropriate treatment should be started and consideration should be given to stopping treatment with warfarin.

Calciphylaxis is most commonly observed in patients with known risk factors such as end-stage renal disease, however cases have also been reported in patients with normal renal function.

MHRA/CHM advice: Warfarin — be alert to the risk of drug interactions with tramadol (June 2024)
The MHRA has received a Coroner's report regarding the death of a patient from a bleed on the brain after taking warfarin with tramadol. Healthcare professionals are reminded that:

There is a risk of increased INR when warfarin and tramadol are taken together which can lead to potentially life-threatening bruising and bleeding
Caution should be exercised when warfarin is prescribed alongside other drugs due to the risk of drug interactions
Dose adjustments for warfarin and/or additional INR monitoring should be considered when starting concomitant tramadol or other medicines

Patients and carers should be advised of the increased risk of bleeding due to drug interactions with warfarin, to inform their healthcare professional that they are on warfarin treatment before taking any new medicines, and to seek medical treatment and have an urgent INR test if any signs or symptoms of a major bleeding event occur.

Contra-indications

For all vitamin K antagonists

Avoid use within 48 hours postpartum
Haemorrhagic stroke
Significant bleeding

Cautions

For all vitamin K antagonists

Bacterial endocarditis (use only if warfarin otherwise indicated)
Conditions in which risk of bleeding is increased
History of gastro-intestinal bleeding
Hyperthyroidism
Hypothyroidism
Peptic ulcer
Recent ischaemic stroke
Recent surgery
Uncontrolled hypertension

Cautions — Further Information: Elderly (STOPP criteria)

Screening Tool of Older Persons' potentially inappropriate Prescriptions (STOPP) criteria to aid medication reviews. Potentially inappropriate:

With concurrent significant bleeding risk, such as uncontrolled severe hypertension, bleeding diathesis, or recent non-trivial spontaneous bleeding (high risk of bleeding)
As part of dual therapy with an antiplatelet agent in patients with stable coronary, cerebrovascular, or peripheral arterial disease, without a clear indication for anticoagulant therapy (no added benefit)
For first deep venous thrombosis without continuing provoking risk factors (e.g. thrombophilia) for longer than 6 months (no proven added benefit)
For first pulmonary embolus without continuing provoking risk factors for longer than 12 months (no proven added benefit)

For warfarin sodium specifically

Postpartum: delay warfarin until risk of haemorrhage is low — usually 5–7 days after delivery.

Side-effects

For all vitamin K antagonists

Common or very common:

Haemorrhage

Rare or very rare:

Alopecia Nausea Vomiting

Frequency not known:

Blue toe syndrome CNS haemorrhage Diarrhoea Fever Haemothorax Jaundice Pancreatitis Skin necrosis Skin reactions

Skin necrosis: increased risk in patients with protein C or protein S deficiency.

For warfarin sodium specifically

Frequency not known:

Calciphylaxis Hepatic function abnormal

Conception, Pregnancy & Breast Feeding

Conception and Contraception

For all vitamin K antagonists: Women of child-bearing age should be warned of the danger of teratogenicity.

Pregnancy — For all vitamin K antagonists

Should not be given in the first trimester of pregnancy. Warfarin, acenocoumarol, and phenindione cross the placenta with risk of congenital malformations, and placental, fetal, or neonatal haemorrhage, especially during the last few weeks of pregnancy and at delivery.

Therefore, if at all possible, they should be avoided in pregnancy, especially in the first and third trimesters (difficult decisions may have to be made, particularly in women with prosthetic heart valves, atrial fibrillation, or with a history of recurrent venous thrombosis or pulmonary embolism).

Stopping these drugs before the sixth week of gestation may largely avoid the risk of fetal abnormality.

Pregnancy — For warfarin sodium specifically

Babies of mothers taking warfarin at the time of delivery need to be offered immediate prophylaxis with intramuscular phytomenadione (vitamin K1).

Breast Feeding

For warfarin sodium: Not present in milk in significant amounts and appears safe. Risk of haemorrhage which is increased by vitamin K deficiency.

Hepatic & Renal Impairment

Hepatic Impairment

For all vitamin K antagonists: In general, manufacturers advise caution in mild to moderate impairment; avoid in severe impairment.

Renal Impairment

For warfarin sodium: Use with caution in mild to moderate impairment.

Monitoring

In severe renal impairment, monitor INR more frequently.

Monitoring Requirements

For all vitamin K antagonists

The baseline prothrombin time should be determined but the initial dose should not be delayed whilst awaiting the result.

It is essential that the INR be determined daily or on alternate days in early days of treatment, then at longer intervals (depending on response), then up to every 12 weeks.

Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing.

Patient and Carer Advice

For all vitamin K antagonists

Anticoagulant treatment booklets should be issued to all patients or their carers. These booklets include advice for patients on anticoagulant treatment, an alert card to be carried by the patient at all times, and a section for recording of INR results and dosage information.

In England, Wales, and Northern Ireland, they are available for purchase from:
3M Security Print and Systems Limited, Gorse Street, Chadderton, Oldham OL9 9QH. Tel: 0845 610 1112

GP practices can obtain supplies through their Local Area Team stores.

NHS Trusts can order supplies from: https://cmswebshop.corp.xerox.com/NHS/Login.aspx

In Scotland, treatment booklets and starter information packs can be obtained by emailing [email protected] or by fax on (0131) 6299 967.

Electronic copies of the warfarin anticoagulant alert card and record booklet are also available as risk minimisation materials at: https://www.medicines.org.uk/emc/rmm-directory/

For warfarin sodium specifically

Anticoagulant card to be provided.

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution.

Available Forms

Oral tablet, Oral suspension

NICE Clinical Knowledge Summaries

Warfarin Management Guidance

Complete NICE CKS guidance for oral anticoagulation with warfarin — from age 16 years onwards. Click any section to expand.

NICE CKS — Anticoagulation Oral

Warfarin — Complete Management

NICE Clinical Knowledge Summaries — Scenario: Warfarin. Covers starting treatment, duration, contraindications, drug interactions, surgery, monitoring, target INRs, out-of-range management, patient advice, and self-testing.

Source: NICE CKS · Last revised August 2025

1. Starting Warfarin Treatment

Baseline Investigations

Full blood count, liver function tests and coagulation screen, including prothrombin time (PT) or INR measurements, should be taken before starting treatment with warfarin.

Induction Dose

Typical Induction

10 mg daily for 2 days — but this should be tailored to individual requirements.

A lower starting dose is often more suitable for:

Frail or elderly people
People with a low body weight
People with liver disease or cardiac failure
People at high risk of bleeding

Subsequent doses depend on the PT, reported as an INR. INR should be checked daily or on alternate days in the early days of treatment. Once INR has stabilised in the target range, monitoring can be at longer intervals (in line with local protocol).

Special Populations

Protein C deficiency: increased risk of skin necrosis when starting warfarin — therapy should be introduced without a loading dose.
Protein S deficiency: may also be at risk — slow introduction of warfarin is advised.
Seek specialist advice from the haematology or anticoagulation team.

Maintenance Dose

Daily Maintenance

Usually 3–9 mg, taken at the same time each day. Exact dose dependent on INR or other appropriate coagulation tests.

INR should be monitored at regular intervals and maintenance dose adjusted accordingly
A maintenance dose can be omitted if the prothrombin time is excessively prolonged

Concurrent Heparin

Where an immediate effect is required (e.g. in DVT or PE), heparin or LMWH is given concurrently until adequate anticoagulation is achieved. Where there is less urgency, anticoagulant treatment may be initiated with warfarin alone.

For people with atrial fibrillation, there is generally no need to achieve anticoagulation rapidly; a slow-loading regimen is safe and achieves therapeutic anticoagulation in most people within 3–4 weeks.

Basis: BCSH Guidelines 4th ed [Keeling 2011], SIGN Antithrombotics [2013], Cochrane SR [Garcia 2016], SPC [EMC 2025], BNF [2025]

2. Duration of Treatment

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

Indication	Duration
Isolated distal DVT (calf vein thrombosis)	At least 6 weeks
Proximal DVT or PE with known temporary risk factors and low recurrence risk	At least 3 months
Recurrent DVTs or PEs	Long-term
Unprovoked proximal DVT or PE	Consider long-term (balance recurrence vs bleeding risk)

Warfarin can be stopped abruptly without harm when the duration of treatment is completed.

Atrial Fibrillation (AF)

Usually long-term treatment
For cardioversion: target INR should be achieved at least 3 weeks before cardioversion and 4 weeks after (if normal sinus rhythm is maintained)
Long-term warfarin is also required for people at high risk of AF recurring: history of failed cardioversion, structural heart disease (mitral valve disease, LV dysfunction, enlarged LA), prolonged AF (>12 months), previous recurrences

Mechanical Prosthetic Heart Valves

Warfarin treatment is usually long-term.

Basis: BCSH [Keeling 2011], SIGN [2013], NICE AF guideline [2021f], BNF [2025]

3. Contraindications and Cautions

Contraindications

Haemorrhagic stroke
Clinically significant bleeding
Severe hepatic impairment
Within 72 hours of major surgery with risk of severe bleeding
Within 48 hours postpartum
Pregnant women — risk of teratogenicity
People taking drugs where interactions lead to a significantly increased risk of bleeding

Cautions — Use with Care

People aged 65 years or older
Increased risk of bleeding — risk factors include: history of GI bleeding, history of peptic ulceration, recent ischaemic stroke, uncontrolled hypertension, concurrent NSAID use, recent surgery
Postpartum period — delay until risk of haemorrhage is low (usually 5–7 days after delivery)
Thrombophilia — introduce warfarin slowly due to risk of skin necrosis
Thyroid disorders — closely monitor (metabolism depends on thyroid status)
Risk factors for overcoagulation (severe hypertension, severe renal/hepatic impairment) — monitor INR more frequently
Mild to moderate hepatic or renal impairment
Bacterial endocarditis
Risk of falling

Factors That May Exaggerate Warfarin Effect

Weight loss Acute illness Smoking cessation

Factors That May Reduce Warfarin Effect

Weight gain Diarrhoea Vomiting

Basis: SPC [EMC 2025], BNF [2025]

4. Adverse Effects

Bleeding is a common adverse effect and can occur in any part of the body. Advise person to seek immediate medical advice if spontaneous bleeding occurs and does not stop, including: bruising, bleeding gums, nosebleeds, prolonged bleeding from cuts, blood in urine/stools, coughing up blood, unusually heavy periods, severe headaches, or abdominal pain.

Antidote

Reversal Agent

Vitamin K1 (phytomenadione) is indicated as antidote to warfarin in treatment of haemorrhage or threatened haemorrhage.

Other Adverse Effects

Rare or very rare:

Alopecia Nausea Vomiting

Frequency unknown:

Blue toe syndrome Diarrhoea Fever Haemothorax Jaundice Pancreatitis Skin reactions Abnormal hepatic function

Skin Necrosis

Presents as painful, localised skin lesions (thrombosis of venules and capillaries) within subcutaneous fat
Associated with high induction doses and protein C or protein S deficiency
Lesions occur in areas of fatty tissue (breasts, abdomen, extremities)
Stop warfarin if skin necrosis is suspected

Calciphylaxis

Rare syndrome of vascular calcification with cutaneous necrosis, associated with high mortality
Mainly occurs in people with end-stage renal disease on dialysis or known risk factors
Rare cases reported in people taking warfarin without renal disease
Advise to seek urgent medical advice if painful skin rash develops
Consider stopping warfarin if diagnosed

Basis: SPC [EMC 2024e, 2025], BNF [2025], MHRA DSU Calciphylaxis [2016a]

5. Key Drug Interactions

Warfarin has a narrow therapeutic range — care is required with all concomitant therapy. Check INR 3–5 days after starting a new interacting drug.

Drugs to AVOID (concomitant use should be avoided if possible)

Drug / Class	Note
Clopidogrel and dipyridamole	Increased bleeding risk
NSAIDs (including topical formulations)	GI bleeding risk + pharmacodynamic interaction
DOACs (dabigatran, rivaroxaban)	Dual anticoagulation — over-anticoagulation
UFH, heparin derivatives, LMWHs	Except during initial warfarin loading
GP IIb/IIIa antagonists (e.g. tirofiban)	Severely increased bleeding risk
SSRIs and SNRIs	Impaired platelet function + possible PK interaction
Azoles — fluconazole and miconazole	Miconazole oral gel should be avoided

Drugs That May ENHANCE Warfarin Effect (monitor INR closely)

Drug / Substance	Clinical Note
Alcohol	Avoid binge drinking; heavy drinkers or liver disease patients should avoid warfarin or alcohol
Amiodarone	Interaction persists for a month or more after amiodarone is stopped
Macrolides, metronidazole	Monitor INR closely when prescribed
SSRIs, SNRIs, some TCAs, mirtazapine	Combined PK and platelet effects
Aspirin / aspirin-containing products	Avoid high-dose; if low-dose indicated, monitor and consider gastroprotection
Azoles — fluconazole, miconazole, voriconazole	Including topical/intravaginal miconazole
Cranberry juice	INRs >8 have occurred
Pomegranate juice	Increase in INR may occur
Tramadol	Risk of life-threatening bleeding (MHRA alert June 2024)
Corticosteroids	Variable effect on INR
Direct-acting antivirals (Hep C)	Monitor INR closely
Fibrates	Avoid if possible, or reduce warfarin dose
Glucosamine	Avoid concurrent use
NSAIDs (including topical)	Avoid; if must use, monitor and counsel on GI bleeding signs
Tamoxifen	Avoid or reduce warfarin dose
Thyroxine	Monitor closely on starting/titrating

Drugs That May REDUCE Warfarin Effect (monitor INR, increase dose as needed)

Drug / Substance	Clinical Note
St John's Wort	Stop; moderate clinical reduction in effect
Griseofulvin	Enzyme induction
Rifampicin	Potent enzyme inducer
Carbamazepine	Enzyme induction
Phenobarbital / primidone	Reduced effect within 2–4 days, persists up to 6 weeks after stopping
Phenytoin	INR may be affected for up to 6 weeks after stopping
Vitamin K-containing products	Enteral feeds, supplements, large amounts of green vegetables/green tea
Chronic heavy alcohol use	May induce warfarin metabolism

Additional Drugs Requiring INR Monitoring (especially in elderly)

Allopurinol Azathioprine Grapefruit juice Influenza vaccine Methylphenidate Orlistat Paracetamol (prolonged use) PPIs Quinolone antibiotics Statins (fluvastatin/rosuvastatin) Stopping smoking Zafirlukast

Basis: BCSH [Keeling 2011], ESC AF Guidelines [Van Gelder 2024], SPC [EMC 2025], BNF [2025], MHRA DSUs [2016b, 2017, 2024], Wang SR 2021, Rahman 2024, Preston Drug Interactions 2025

6. Surgery and Dental Treatment

General Principles

The decision to stop warfarin and when to stop depends on the person's thromboembolic risk and the bleeding risk of the procedure. All patients and caregivers should receive written information from the operating physician indicating the date/time of the intervention and the date/time of the last warfarin intake.

Management by Procedure Type

Scenario	Management
Minor surgery	Can generally be performed with INR <2.5. Follow local recommendations.
Major surgery	Stop warfarin 3–5 days prior. High thromboembolic risk patients (VTE within 3 months, AF with previous stroke/TIA, mitral mechanical valve) may need bridging with treatment-dose LMWH.
Emergency surgery (can delay 6–12h)	Give IV phytomenadione (vitamin K1).
Emergency surgery (cannot delay)	Dried prothrombin complex + IV phytomenadione. Check INR before surgery.
Anticoagulation must continue	Reduce INR to <2.5, start heparin.

Reinstate warfarin once adequate haemostasis is achieved and the person has oral intake.

Dental Procedures

Key Rule

In most cases, warfarin need NOT be stopped before routine dental surgery (e.g. tooth extraction).

Check INR ideally no more than 24 hours before dental surgery (in stable patients, no more than 72 hours before)
INR below 4: treatment can continue without interrupting anticoagulation
INR above 4: delay treatment until INR has been reduced to less than 4

The risk of significant bleeding in people with a stable INR within 2–4 is very small, but the risk of thrombosis may be increased if oral anticoagulants are temporarily discontinued.

Basis: BSH Peri-operative guideline [2022], SDCEP Dental guideline [2022], SPC [EMC 2025]

7. Monitoring

INR Measurement

INR is most accurately measured in venous blood samples
Many anticoagulation clinics use capillary blood samples for convenience
IV drug users and people with hepatitis B/C or HIV may need specialist clinic referral

Monitoring Frequency

Phase	Frequency
Starting warfarin	Daily or on alternate days
Dose titration	At longer intervals (depending on response)
Stable maintenance	Up to every 12 weeks (if agreed locally)

More Frequent Monitoring Recommended For

High intensity of anticoagulation (INR >4.0)
Age 65 years or older
Highly variable INRs
History of gastrointestinal bleeding
Uncontrolled hypertension, cerebrovascular disease, or serious heart disease
Risk of falling
Anaemia, malignancy, trauma
Renal insufficiency or impaired hepatic function
Haemorrhagic blood dyscrasias
Hypermetabolic states (hyperthyroidism, acute illness)
Vitamin K deficiency, diarrhoea
Taking interacting drugs
Those for whom adherence may be difficult

Poor Anticoagulation Control — Reassess if:

Two INR values >5, or one INR value >8, within the past 6 months; OR two INR values <1.5 within the past 6 months; OR TTR <65%.

Address contributing factors: cognitive function, adherence, illness, interacting drugs, lifestyle/diet/alcohol. If poor control cannot be improved, evaluate risks and benefits of alternative strategies — seek specialist advice.

Genetic Variability

CYP2C9 or VKORC1 polymorphisms — if person or family member is known to have these, extra care is warranted.

Basis: BCSH [Keeling 2011], NICE AF guideline [2021f], SPC [EMC 2025], BNF [2025]

8. Monitoring During COVID-19 Pandemic

Acute illness (including COVID-19) may exaggerate warfarin effect — may need dose reduction
Continued INR monitoring is important in suspected/confirmed COVID-19 — manage early to reduce bleeding risk
Warfarin may interact with antibacterials and antivirals — follow SPC advice
If switching warfarin to DOAC: stop warfarin BEFORE starting DOAC to reduce risk of over-anticoagulation

Remind the Person to:

Follow warfarin instructions carefully (including patient information leaflet)
Notify GP/healthcare team if: COVID-19 symptoms/confirmed; unwell; changed diet/smoking/alcohol; new medicines; unable to attend blood test

Basis: MHRA DSU [2020b], BNF [2025]

9. Target INRs

The maintenance dose depends on the INR during monitoring. Average daily maintenance dose: 3–9 mg (range 1–15 mg in some people). An INR within 0.5 units of target is generally satisfactory.

Target INR 2.5

Indication	Target
Treatment of DVT or PE (including those with antiphospholipid syndrome or recurrence off warfarin)	2.5
Atrial fibrillation	2.5
Cardioversion (higher targets such as 3.0 can be used for up to 4 weeks before to avoid cancellations)	2.5
Mitral stenosis or regurgitation with AF, history of systemic embolism, LA thrombus, or enlarged LA	2.5
Bioprosthesis in mitral position	2.5
Bioprosthetic valve and history of systemic embolism / LA thrombus at surgery / other prothrombotic risk factors	2.5
Acute arterial embolism leading to embolectomy	2.5
Dilated cardiomyopathy	2.5
Post myocardial infarction	2.5

Target INR 3.5

Indication

Recurrent DVT or PE in people currently anticoagulated with INR >2.

Mechanical Prosthetic Heart Valves — Target INR Table

Valve Thrombogenicity	No Patient Risk Factors	With Patient Risk Factors*
Low	2.5	3.0
Medium	3.0	3.5
High	3.5	3.5 (4.0 per ESC/EACTS 2021)

*Patient-related risk factors: mitral/tricuspid/pulmonary position; previous arterial thromboembolism; AF; LA diameter >50 mm; mitral stenosis of any degree; LVEF <35%; LA dense spontaneous echo contrast.

If an embolic event occurs at target INR: consider increasing INR target or adding antiplatelet drug.

Basis: BCSH [Keeling 2011], BNF [2025]

10. INR Not in Range — Management

Ask the person about changes: adherence, missed/extra doses, new medications (including OTC, vitamins, herbal), alcohol, illicit drugs, food/drink intake, general health.

Scenario	Management
Major Bleeding	STOP warfarin. IMMEDIATE emergency admission for IV phytomenadione (vitamin K1) AND dried prothrombin complex concentrate (factors II, VII, IX, X). If PCC unavailable, use fresh frozen plasma.
INR >8 WITH minor bleeding	Stop warfarin. Same-day hospital assessment for IV phytomenadione (slow injection). Dose may be repeated after 24h if INR still too high. Restart when INR <5.
INR >8 WITH no bleeding	Stop warfarin. Same-day hospital assessment for phytomenadione. Dose may be repeated after 24h. Restart when INR <5.
INR 5–8 WITH minor bleeding	Stop warfarin. Same-day hospital assessment for consideration of phytomenadione. Restart when INR <5.
INR 5–8 WITH no bleeding	Withhold 1 or 2 doses. Monitor INR closely and alter subsequent maintenance dose. Consider discussing high-risk patients with a specialist — some may be appropriate for oral vitamin K.

Unexpected Bleeding at Therapeutic Levels

Always investigate the possibility of an underlying cause (e.g. unsuspected renal or gastrointestinal tract pathology).

Basis: BCSH [Keeling 2011], SPC [EMC 2025], BNF [2025]

11. Advice to Patients

Have blood tested regularly at agreed intervals
Always take the 'Yellow book' (anticoagulant treatment booklet) to the warfarin clinic
Take warfarin at the same time each day
Do not miss doses or take additional doses without advice
Inform clinic staff if taken too much or missed doses
If a dose is missed: continue as prescribed, never take a double dose
Warfarin levels affected by diet, alcohol, acute illness, and other medications
Seek medical advice before major dietary changes, especially if rich in vitamin K
Limit alcohol to 1–2 drinks per day, never binge drink
Inform healthcare professionals of any lifestyle changes or medication changes
Seek immediate medical advice if: spontaneous/uncontrolled bleeding, sudden severe back pain, difficulty breathing/chest pain
May need to temporarily stop warfarin for surgery/dental treatment
Expect to bruise more easily; use soft toothbrush and electric razor

Women of Childbearing Potential

Warfarin is a known teratogen. Effective contraception must be used during treatment.

Warfarin crosses placenta — risk of congenital malformations, placental/fetal/neonatal haemorrhage (especially first and third trimesters)
Pre-pregnancy counselling recommended for all women of reproductive age with mechanical heart valve — delivered by specialist MDT
If pregnancy confirmed: refer urgently (ideally seen before 6 weeks gestation) to specialist centre with experienced MDT (obstetrics, cardiology, cardiac surgery, anaesthetics, neonatology, haematology)

Basis: SIGN [2013], BSH Pregnancy guideline [2023], SPC [EMC 2025], BNF [2025]

12. Self-testing and Self-management

Definitions

Type	Description
Self-testing	Person tests own INR but contacts healthcare professional for dose adjustment
Self-management	Person tests own INR AND adjusts warfarin dose using individualised algorithm

Suitability Criteria

Person is physically and cognitively able to perform self-monitoring (or designated carer can)
Adequate supportive educational programme is in place
Person's ability to self-test can be regularly reviewed
Access to trained healthcare professionals for ongoing advice and support
For self-management: must be cognitively able to follow individualised algorithm, sufficiently motivated

NOT Suitable For

Those who fail to attend clinic appointments (unless work/school/access is the barrier)
Those who do not adhere to dosage instructions
Those who do not wish to do so

Training Requirements

Informed consent including agreement to record results and participate in QA scheme
Theoretical aspects of anticoagulation management
How to monitor, record results, and frequency of monitoring
Problems with monitoring (identifying sources of error)
Drug interactions, nutrition, alcohol, illness, and travel
How to recognise and treat complications
Target INR for their condition and importance of maintaining within 0.5 of target

Ongoing Requirements

Review at least every 6 months by responsible clinician
Access to trained healthcare professional for advice (phone or in person)
Participate in device QA — either UKNEQAS or regular clinic attendance for venous/POC comparison
Check each batch of test strips is working correctly

Device

CoaguChek INRange system. Not available on NHS, though some test strips and lancets are available on prescription.

Basis: BSH guideline [Jennings 2014], NICE guideline CoaguChek [2017], Cochrane SR [Heneghan 2016], Connock SR 2007, Ansell international consensus 2005

NICE CKS content is copyright © Clarity Informatics Limited (trading as Agilio Software Primary Care).
Extracted 28 March 2026 for Dr Abdul Mannan — Anticoagulation Management Reference

4-Factor PCC — Warfarin Reversal

Complete reference for urgent reversal of vitamin K antagonist therapy with Prothrombin Complex Concentrate

Rapid Reversal Dose Calculator Clinician Videos

PCC Dose Calculator

Enter patient's pre-treatment INR and body weight to calculate the recommended PCC dose. Dosing is based on Factor IX units. Weight is capped at 100 kg for dosing purposes.

Pre-treatment INR

Body Weight (kg)

Pre-treatment INR	Dose (units/kg)	Max Dose (units)
2 to < 4	25 units/kg	2,500 units
4 to 6	35 units/kg	3,500 units
> 6	50 units/kg	5,000 units

Important Safety Notes

Weight capped at 100 kg for dosing. Must administer concurrently with vitamin K. Repeat dosing not recommended. Contraindicated in DIC, HIT, and known anaphylaxis to PCC components.

1. What is 4-Factor PCC?

4-Factor PCC is the only 4-Factor Prothrombin Complex Concentrate indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g. warfarin) therapy in adult patients with:

Acute major bleeding
Need for urgent surgery or other invasive procedure

PCC is for intravenous use only.

PCC is a purified, heat-treated, nanofiltered, lyophilised, non-activated 4-factor prothrombin complex concentrate. It instantly restores coagulation factors to normal levels, achieving rapid and complete warfarin reversal.

Guideline Recommendations

Multiple treatment guidelines recommend considering 4-Factor PCC for warfarin reversal:

ACG-CAG — American College of Gastroenterology / Canadian Association of Gastroenterology
AHA/ASA — American Heart Association / American Stroke Association
ACC — American College of Cardiology
ACEP — American College of Emergency Physicians
ACS — American College of Surgeons
ASH — American Society of Hematology
NCS + SCCM — Neurocritical Society + Society of Critical Care Medicine
CHEST — American College of Chest Physicians

2. Mechanism of Action

PCC rapidly restores factor levels to normal after infusion, regardless of INR. All factor levels were above 50% as early as 30 minutes after administration.

Key Factors in Coagulation

Factors II and X are the key factors in the coagulation cascade
Factor II is the most thrombogenic in achieving haemostasis

Composition

PCC replaces only what is needed for urgent warfarin reversal and contains:

VK-Dependent Factors

Factor II
Factor VII
Factor IX
Factor X

Antithrombotic Proteins

Protein C
Protein S

Key Product Characteristics

Non-activated formulation
Contains high levels of antithrombin III and minimal heparin
Must be administered concurrently with vitamin K
36-month room-temperature storage prior to reconstitution
Supplied in Mix2Vial package, dosed intravenously after reconstitution
Coagulation factors in PCC are approximately 25 times more concentrated than in plasma

How PCC Differs from Plasma and 3F-PCC

VKAs like warfarin inhibit synthesis of fully functional vitamin K-dependent coagulation factors. PCC directly replaces these factors.
Unlike 3F-PCCs (indicated for haemophilia only), 4-Factor PCC has an FDA indication for urgent warfarin reversal.
Unlike fresh frozen plasma (FFP), PCC replaces only those coagulation factors needed, without excess volume.

3. Efficacy

PCC demonstrated superiority over plasma in 3 of 4 efficacy endpoints in 2 head-to-head clinical trials.

Trial Results Summary

Superior haemostatic efficacy in the Urgent Surgery/Invasive Procedures trial
Equally effective haemostasis in the Acute Major Bleeding trial
Faster INR reduction (to 1.3 or below at 30 minutes after end of infusion) in both head-to-head trials

Why Vitamin K Must Be Used with PCC

The administration of vitamin K is expected to maintain factor levels once the effects of PCC have diminished. The dose of vitamin K is not specified in the PCC prescribing information and should follow current treatment guidelines.

4. Speed & Less Volume vs Plasma

Time to Surgery

Significantly shorter time to surgery with PCC vs plasma:

3.6 h

PCC median

8.5 h

Plasma median

Approximately 5 hours faster with PCC.

Infusion Time Comparison

PCC is approximately 7 times faster than plasma for infusion:

PCC mean infusion time: < 25 minutes (21 ± 14 min; alternatively 24 ± 32 min)
Plasma mean infusion time: > 2 hours (141 ± 113 min; alternatively 169 ± 143 min)

Volume Requirements

PCC requires approximately 85% less volume than plasma:

PCC mean infusion volume: 90 mL (± 32 mL); alternatively 105 mL (± 37 mL)
Plasma mean infusion volume: 819 mL (± 231 mL); alternatively 865 mL (± 269 mL)

Concentration Advantage

PCC is approximately 25 times more concentrated than plasma
3 vials of PCC (average 2500 IU single dose) equal approximately 10-12 units of plasma

Practical Advantages

No need for thawing or ABO typing
More concentrated formulation reduces volume burden

Healthcare Cost and Hospital Stay

Patients treated with PCC had average charges 40% less ($84,000 less) than plasma-treated patients
Overall hospital stay was 43% shorter for PCC-treated patients vs plasma

5. Safety Profile

PCC has a safety profile comparable to plasma in clinical trials.

Adverse Reactions in Clinical Trials

Most frequent adverse reactions (≥2.8% incidence) in PCC-treated patients (N=191) vs Plasma (N=197):

Headache
Nausea/vomiting
Hypotension
Anaemia

The most serious adverse reactions were thromboembolic events, including stroke, pulmonary embolism, and deep vein thrombosis.

Contraindications

PCC is contraindicated in the following patients:

Known anaphylactic or severe systemic reactions to PCC or any of its components (including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III, and human albumin)
Disseminated intravascular coagulation (DIC)
Heparin-induced thrombocytopenia (HIT) — because PCC contains heparin

Boxed Warning

WARNING: ARTERIAL AND VENOUS THROMBOEMBOLIC COMPLICATIONS

Patients being treated with VKA therapy have underlying disease states that predispose them to thromboembolic events. The potential benefits of reversing VKA should be weighed against the risk of thromboembolic events, especially in patients with a history of such events.

Both fatal and nonfatal arterial and venous thromboembolic complications have been reported in clinical trials and postmarketing surveillance. Monitor patients receiving PCC for signs and symptoms of thromboembolic events.

Infection Risk

PCC is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated. Report suspected viral transmissions to the manufacturer.

6. Thromboembolic Events & Mortality

A major postmarketing observational study evaluated TE events and all-cause mortality in a real-world setting.

Study Overview

"Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding"

Published in: Journal of Thrombosis and Thrombolysis. This was an FDA postmarketing requirement observational study, conducted in partnership with Kaiser Permanente, CSL Behring, and board-certified physicians.

Study Design

Multicentre, observational study using Kaiser Permanente databases
Comparison of 45-day risk of TE events in matched real-world cohort of hospitalised adults
Total: 2,238 patients with no recent history of TE events (PCC: N=1,119 | Plasma: N=1,119)
Diverse patient population across spectrum of age, sex, race/ethnicity, and socioeconomic status

Bleeding Types Included

68% ICH (N=1,514) 31% GI (N=689) 1% Other (N=35)

Primary Outcome: TE Events at 45 Days

No increased risk of TE events vs plasma

Adjusted Hazard Ratio (aHR): 0.76, 95% CI: 0.49–1.16. Sensitivity analyses at 7-day and 14-day timepoints also showed no significant adjusted differences in TE event risk.

Secondary Outcome: All-Cause Mortality at 45 Days

41% risk reduction in adjusted all-cause mortality with PCC vs plasma

Adjusted Hazard Ratio (aHR): 0.59, 95% CI: 0.47–0.73. Confirmed in sensitivity analyses.

7. Dosing

PCC is dosed based on units of Factor IX. A single dose is determined by the patient's pretreatment INR and body weight.

Units refer to international units. Dosing is based on body weight up to but not exceeding 100 kg. For patients weighing more than 100 kg, the maximum dose should not be exceeded.

Administration

Administer by intravenous infusion at a rate of 0.12 mL/kg/min (approximately 3 units/kg/min)
Maximum infusion rate: 8.4 mL/min (approximately 210 units/min)
Administer concurrently with vitamin K
Administer through a separate infusion line

Repeat dosing is not supported by clinical data and is not recommended.

8. Reconstitution & Administration

Reconstitution Using the Mix2Vial Transfer Set

A step-by-step reconstitution video is available on the manufacturer's website.

Administration Instructions

Do not mix PCC with other medicinal products; administer through a separate infusion line
Use aseptic technique when administering PCC
Administer at room temperature
Administer by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min)
Administer concurrently with vitamin K
No blood should enter the syringe, as there is a possibility of fibrin clot formation

Storage After Reconstitution

PCC must be used within 4 hours following reconstitution
Reconstituted product can be stored at 2-25°C
If cooled, the solution should be warmed to 20-25°C prior to administration
Do not freeze the reconstituted product
Discard partially used vials

Storage Prior to Reconstitution

PCC is for single use only and contains no preservatives
Store between 2-25°C (36-77°F), not to exceed 25°C (77°F) — allows room-temperature storage
Stable for 36 months from the date of manufacture, up to the expiration date on the carton
Store the vial in the original carton to protect it from light

9. Patient Case Studies

Three patient case studies demonstrate PCC use in different clinical scenarios.

Case 1: ICH

Urgent warfarin reversal in a patient presenting with intracranial haemorrhage.

Case 2: GI Bleed

Urgent warfarin reversal in a patient presenting with gastrointestinal bleeding.

Case 3: Ortho Fracture

Urgent warfarin reversal in a patient requiring emergency orthopaedic surgery.

10. Clinician Videos & Podcasts

A library of clinician videos and podcasts covering PCC for warfarin reversal. Click any title to view.

Video 1: Why Your Peers Turn to PCC for Urgent Warfarin Reversal

Presenter: Dr. Fariborz Rezai, Critical Care Physician — Discusses why PCC is his preferred choice for urgent warfarin reversal. 13 min 18 sec

Watch Video

Video 2: Dosing and Reconstitution with PCC

Presenter: Dr. Megan Rech, Emergency Medicine Pharmacist & Research Health Scientist — Reviews dosing guidance, the calculator tool, and step-by-step reconstitution. 20 min 24 sec

Watch Video

Video 3: The Value of PCC Over Plasma

Presenter: Dr. Katleen Chester, Clinical Pharmacist Specialist — Compares PCC vs plasma on healthcare costs, hospital stay duration, and clinical outcomes. 13 min 15 sec

Watch Video

Video 4: Clinical Value of PCC — Chapterised Presentation

Presenter: Dr. David Rose — Comprehensive chapterised review covering Introduction, Clinical Considerations, GI Bleed Case, ICH Case, Efficacy Data, Postmarketing Study, Safety Profile, and Conclusion. 11 min 52 sec

Watch Video

Podcast 1: Warfarin, Severe GI Bleeds & Haemodynamic Instability

Host: Jennifer Caudle, DO (ReachMD) | Guest: Dr. Majed Refaai, Transfusion Medicine & Coagulation Specialist — Discusses PCC as preferred treatment for warfarin patients with haemodynamically significant GI bleeds. 16 min 40 sec

Listen to Podcast

Podcast 2: Practice Protocols — The Case for 4F-PCC

Host: Jennifer Caudle, DO (ReachMD) | Presenter: Dr. Michelle Kincaid — Reviews data from the largest study to date on thromboembolic events and mortality associated with 4F-PCC use, with practice protocol recommendations. 14 min 43 sec

Listen to Podcast

Explore the PCC Clinician Video Library

Why your peers turn to PCC for urgent warfarin reversal time and time again — full collection of clinician videos and podcasts.

Browse All

11. Frequently Asked Questions

Can PCC be prepared and infused faster than plasma?

In clinical trials, infusion with PCC is approximately 7 times faster than with plasma. In the Acute Major Bleeding trial, mean infusion time was 24 minutes for PCC vs 169 minutes for plasma. Unlike FFP, PCC does not require thawing or ABO typing.

How effective was PCC for urgent warfarin reversal in clinical trials?

PCC demonstrated superiority over plasma in 3 of 4 efficacy endpoints in 2 head-to-head trials: superior haemostatic efficacy in the Urgent Surgery/Invasive Procedures trial, equally effective haemostasis in the Acute Major Bleeding trial, and faster INR reduction (to 1.3 or below at 30 minutes after end of infusion) in both trials.

How is PCC stored?

Prior to reconstitution: For single use only, contains no preservatives. Store between 2-25°C (36-77°F). Stable for 36 months from manufacture.

After reconstitution: Must be used within 4 hours. Store at 2-25°C. Do not freeze; discard partially used vials.

Why is consignment ordering useful?

Consignment can help ensure your hospital always has the minimum adequate supply of PCC for life-threatening bleeding emergencies requiring urgent warfarin reversal.

Support & Contact

Medical Questions: CSL Behring Medical Affairs — 24/7 support line: 1-800-504-5434 (option 1) | Email: [email protected]

Other Support (Ordering, Reimbursement): 1-855-452-3687

PCC content compiled from publicly available prescribing information for educational reference. Always refer to the full prescribing information and consult specialist guidance before clinical use.
Adverse Reactions: Contact CSL Behring Pharmacovigilance (1-866-915-6958) or FDA MedWatch (1-800-FDA-1088).
Compiled 28 March 2026 for Dr Abdul Mannan — Anticoagulation Management Reference

Select Indication for Anticoagulation

Enter INR Readings

INR Trend Chart

Warfarin Drug Interaction Analyser

TTR-Based Action Guide

BNF Warfarin Monograph

Warfarin Sodium

Warfarin Management Guidance

Warfarin — Complete Management

4-Factor PCC — Warfarin Reversal

PCC Dose Calculator

Critical INR Value